Zoetis Inc. has received marketing authorization from the European Commission for Portela® (relfovetmab), a new monoclonal antibody therapy for alleviating pain associated with osteoarthritis in cats. Portela is the first monoclonal antibody treatment with a three-month dosing interval approved for this use in cats, providing a long-acting solution that targets nerve growth factor (NGF), a key mediator of osteoarthritis pain and inflammation. The approval was based on positive safety and efficacy data, including a nine-month field trial in Europe. Zoetis plans to make Portela commercially available in the European Union in 2026. No other organizations were mentioned as recipients of this regulatory approval.